| Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ... JAMA oncology 4 (2), 173-182, 2018 | 1040 | 2018 |
| Endocrine toxicity of cancer immunotherapy targeting immune checkpoints LS Chang, R Barroso-Sousa, SM Tolaney, FS Hodi, UB Kaiser, L Min Endocrine reviews 40 (1), 17-65, 2019 | 492 | 2019 |
| Insulin granule biogenesis, trafficking and exocytosis JC Hou, L Min, JE Pessin Vitamins & hormones 80, 473-506, 2009 | 315 | 2009 |
| Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study L Min, FS Hodi, A Giobbie-Hurder, PA Ott, JJ Luke, H Donahue, M Davis, ... Clinical Cancer Research 21 (4), 749-755, 2015 | 279 | 2015 |
| Regulation of pancreatic β-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway A Tomas, B Yermen, L Min, JE Pessin, PA Halban Journal of cell science 119 (10), 2156-2167, 2006 | 205 | 2006 |
| Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy L Min, A Vaidya, C Becker European Journal of Endocrinology 164 (2), 303-307, 2011 | 191 | 2011 |
| Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy H Lee, FS Hodi, A Giobbie-Hurder, PA Ott, EI Buchbinder, R Haq, ... Cancer Immunology Research 5 (12), 1133-1140, 2017 | 151 | 2017 |
| The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management M Girotra, A Hansen, A Farooki, DJ Byun, L Min, BC Creelan, ... JNCI Cancer Spectrum 2 (3), pky021, 2018 | 120 | 2018 |
| Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis L Min, FS Hodi Cancer immunology research 2 (1), 15-18, 2014 | 114* | 2014 |
| Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management R Barroso‐Sousa, PA Ott, FS Hodi, UB Kaiser, SM Tolaney, L Min Cancer 124 (6), 1111-1121, 2018 | 112 | 2018 |
| Ipilimumab-induced autoimmune adrenalitis L Min, N Ibrahim The lancet Diabetes & endocrinology 1 (3), e15, 2013 | 108 | 2013 |
| Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series L Min, A Vaidya, C Becker Endocrine Practice 18 (3), 351-355, 2012 | 77 | 2012 |
| The association of arrestin-3 with the human lutropin/choriogonadotropin receptor depends mostly on receptor activation rather than on receptor phosphorylation L Min, C Galet, M Ascoli Journal of Biological Chemistry 277 (1), 702-710, 2002 | 76 | 2002 |
| GnRH-Deficient Phenotypes in Humans and Mice with Heterozygous Variants in KISS1/Kiss1 YM Chan, S Broder-Fingert, S Paraschos, R Lapatto, M Au, V Hughes, ... The Journal of Clinical Endocrinology & Metabolism 96 (11), E1771-E1781, 2011 | 75 | 2011 |
| Effect of activating and inactivating mutations on the phosphorylation and trafficking of the human lutropin/choriogonadotropin receptor L Min, M Ascoli Molecular endocrinology 14 (11), 1797-1810, 2000 | 75 | 2000 |
| Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma C Robert, WJ Hwu, O Hamid, A Ribas, JS Weber, AI Daud, FS Hodi, ... European Journal of Cancer 144, 182-191, 2021 | 73 | 2021 |
| Clinical identification of oncogenic drivers and copy-number alterations in pituitary tumors WL Bi, NF Greenwald, SH Ramkissoon, M Abedalthagafi, SM Coy, ... Endocrinology 158 (7), 2284-2291, 2017 | 63 | 2017 |
| Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma TE Angell, L Min, TJ Wieczorek, FS Hodi Genes & diseases 5 (1), 46-48, 2018 | 62 | 2018 |
| Improving the management of diabetes in hospitalized patients: the results of a computer-based house staff training program A Vaidya, S Hurwitz, M Yialamas, L Min, R Garg Diabetes Technology & Therapeutics 14 (7), 610-618, 2012 | 62 | 2012 |
| Dynamic kisspeptin receptor trafficking modulates kisspeptin-mediated calcium signaling L Min, K Soltis, ACS Reis, S Xu, W Kuohung, M Jain, RS Carroll, ... Molecular endocrinology 28 (1), 16-27, 2014 | 58 | 2014 |
